AMG-458 is primarily investigated for its potential in cancer treatment, particularly as an inhibitor of c-Met, a receptor tyrosine kinase involved in tumor growth and metastasis. It is studied for its ability to block c-Met signaling pathways, which are often dysregulated in various cancers, including lung, liver, and gastric cancers. By targeting these pathways, AMG-458 aims to inhibit tumor proliferation, invasion, and angiogenesis, making it a promising candidate for therapeutic development in oncology. Research focuses on its efficacy in preclinical models and its potential use in combination with other anticancer therapies to enhance treatment outcomes.